We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.08 | 14.16 | 13.96 | 14.15 | 7,051,252 | 01:00:00 |
By Maria Armental
U.S. health regulators have rejected Perrigo Co.'s (PRGO) generic version of Teva Pharmaceutical Industries Ltd.'s ProAir inhalation aerosol, Perrigo said Friday.
Perrigo, which had targeted releasing the generic in the fourth quarter and had built a roughly 9-cent-a-share projected benefit to its 2018 financial forecast, said it had a teleconference call with the Food and Drug Administration late Thursday afternoon and that it expects to receive what is known as a complete response letter, detailing the reasons for the rejection.
Over all, Perrigo had projected annual profit of $2.90 to $3.30 a share and $5.05 to $5.45 a share on an adjusted basis.
Perrigo's stock fell 4% to $74.10 in after-hours trading while Teva's was down slightly at $19.30.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
May 11, 2018 17:13 ET (21:13 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions